ContextVision enters Data Quality market with organ-specific enhancements

18 Jul 2024 08:00 CEST

Stockholm, Sweden, July 18, 2024 - ContextVision, a leading provider of medical
image processing and analysis technology, is excited to announce a strategic
evolution of its Image Quality business. In response to the rapidly advancing
digital transformation in healthcare, ContextVision is expanding its product
pipeline into Data Quality, preparing to establish vital clinical and commercial
partnerships.

Expanding product pipeline from Image Quality to Data Quality

ContextVision is committed to expanding its Image Quality business, which today
focuses on enhancing medical image quality for a radiologists' interpretation.
Alongside, ContextVision is pioneering a new Data Quality business aimed at
machine-aided interpretation. Data Quality is a natural extension of
ContextVision's Image Quality business that aims to build organ-specific
applications. This new product pipeline will improve physiological
quantification from imaging modalities, enabling the implementation of digital
biomarkers. By facilitating both a better interpretation and quantification of
physiological findings from medical imaging, ContextVision's innovative products
will provide powerful tools to our customer's diagnostic solutions.

Focusing on organ-specific enhancements for improved disease management

Leveraging decades of expertise in image processing, such as resizing, de
-noising and segmentation, ContextVision is now targeting organ-specific image
enhancements to streamline disease management. These advancements will enable
higher performance for AI/Machine Learning algorithms and clinical-decision
support applications, especially for near-patient imaging. By enhancing specific
organ imaging, ContextVision will support its customers in delivering faster and
more definitive diagnosis with Point-of-Care Ultrasound solutions.

"Our new Data Quality business with the development of organ-specific imaging
solutions underscores our dedication to pushing the boundaries of medical
technology. By integrating these advancements, we aim to deliver unparalleled
precision in diagnostics. We are now in the final stages of signing new clinical
and commercial partnerships which will lay a strong foundation for what lies
ahead in our expanded product offering. It is immensely gratifying to be
contributing to such significant advancements in global healthcare", says Gerald
Pötzsch, CEO of ContextVision.

Strategic growth and expansion

With an ambitious vision for the future, ContextVision is poised to embark on a
growth trajectory fueled by organic growth and potentially supported by
inorganic opportunities. The company is looking into different strategic
options, particularly focused on expanding its capabilities in acquisition
intelligence, and thereby, optimizing imaging parameters for specific modalities
earlier in the imaging chain. This will enable customers to optimize the final
output of their imaging products through corrective actions or enhancements
during the initial stages of image formation.

For more information, please contact:

ir@contextvision.com

About ContextVision

ContextVision is a medical technology software company specialized in image
analysis and artificial intelligence. As the global market leader within image
enhancement, we are a trusted partner to leading manufacturers of ultrasound, X
-ray and MRI equipment around the world. Our expertise is to develop powerful
software products, based on proprietary technology and artificial intelligence
for image-based applications. Our cutting-edge technology helps clinicians
accurately interpret medical images, a crucial foundation for better diagnosis
and treatment. The company, established in 1983, is based in Sweden with local
representation in the U.S., Japan, China and Korea. ContextVision is listed on
the Oslo Stock Exchange under the ticker CONTX.

More information:
Access the news on Oslo Bors NewsWeb site